Skip to main navigation
Liquidia Logo
Skip to main content
Liquidia Logo

    Home

  • Home
  • About

  • About Liquidia
    • Overview
    • Leadership
    • Board of Directors
  • Products and Pipeline

  • Pipeline and Products
    • Pipeline
    • Commercial Products
    • PRINT® Technology
    • Publications
  • IR Nav

  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • IR Resources
      • Investor FAQs
      • IR Contact
      • Email Alerts
      • Proxy Online
  • Careers

  • Careers
    • Overview
    • Jobs
    • Benefits
    • Principles
  • Contact Us

  • Contact Us
    • Overview
    • Map/Directions

SEC Filing

IR Nav

Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
    Analyst Coverage Stock Quote & Chart Historical Price Lookup Investment Calculator
  • Corporate Governance
    Documents & Charters Leadership Board of Directors Committee Composition
  • SEC Filings
  • IR Resources
    Investor FAQs IR Contact Email Alerts Proxy Online

SEC Filing Details

Document Details

Form
SC 13G/A
Filing Date
Feb 1, 2023
Document Date
Feb 1, 2023
Form Description
An amendment to the SC 13G filing
Filing Group
Other
Company
Liquidia
Issuer
LIQUIDIA CORP

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

IR Tools

  • Print Page
  • Share
  • RSS
Liquidia Logo

419 Davis Drive, Suite 100, Morrisville, NC 27560
Tel +1 919-328-4400
Fax +1 919-328-4402

Socials

© 2023 Liquidia Corporation All Rights Reserved.

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection.

Legal Nav

  • Legal
  • Privacy
  • Cookies
  • Social Media
  • Facebook
  • Twitter
  • LinkedIn